Features of Monitoring Patients with Primary and Advanced Stages of Glaucoma in Krasnodar Territory

Purpose: to analyze the monitoring of patients with primary and advanced stages of glaucoma, who applied to the private clinic “Tri-Z” (Krasnodar).

Patients and Methods. A total of 3 524 patients underwent screening with a diagnosis of glaucoma for all over 2018 at the clinic, of which 55.6 % were diagnosed with primary and advanced glaucoma. The criterion for inclusion in the study was primary glaucoma of the initial and advanced stages, elimination criteria: high degree of refraction errors, retinal detachment in anamnesis, proliferative diabetic retinopathy, AMD exudative forms, congenital forms of glaucoma, secondary types of glaucoma.

Results: The average age of patients was 68.44 ± 8.142 years, women were 71 %, men — 29 %. The average duration of glaucomatous history was 3.48 ± 3.525 years. POAG was found in 85.3 % of cases, PACG in 14.7 % of cases. Glaucoma without concomitant PEX was observed in 44.7 % cases, with signs of PEX in 55.3 % cases. In stage I of glaucoma, the majority of patients (42.7 %) received APG and in 27.1 % cases a fixed combination of ICA + BB. In stage II glaucoma, the majority of patients (26.5 %) received a fixed combination of ICA + BB, in 18.8 % of cases, the combination of APG + ICA + BB and in 17.7 % — APG. The share of laser interventions: LTP — 14.7 %, SLT — 4.1 %, peripheral iridectomy — 10 %, YAG-GP — 0.8 %, SLT + YAG-GP — 0.8 %, peripheral iridectomy + SLT — 0.5 %. The share of surgical interventions: at glaucoma stage I non-penetrating deep sclerectomy (NPDS) — 3.4 %; at stage II NPDS — 10.9 %, repeated NPDS — 0.5 %, deepsclerectomy — 2.2 %; phacoemulsification + IOL — 21.9 % of cases.

Conclusion: In the study, we noted the following features: use, including as a starting therapy, effective drugs or their combinations; the preferred use of fixed combinations; prioritization of non-preservative therapy; high frequency of laser interventions in the anterior eye segment; use of peripheral laser iridectomy in the overwhelming majority of cases when PACG is detected; early transition to surgical treatment.

1. WHO (1988) Coding instructions for the WHO/PBL eye examination record (version III). Geneva: World Health Organization. Available: http://whqlibdoc.who. int/ hq/1988/PBL_88.1.pdf. Accessed 18 January 2018.

2. Pascolini D., Mariotti S.P. Global estimates of visual impairment: 2010. Br. J. Ophthalmology. 2012;96(5):614–618. DOI: 10.1136/bjophthalmol-2012-301861.

3. Machekhin V.A., Fabrikantov O.L. With regard to early detection and medical examination of patients with glaucoma. Practical medicine = Prakticheskaya meditsina. 2013;3-1(69):44–47 (In Russ.).

4. Rossetti L., Digiuni M., Montesano G., Centofanti M., Fea A.M., Iester M., Frezzotti P., Figus M., Ferreras A., Oddone F., Tanga L., Rolle T., Battaglino V., Posarelli C., Motolese I., Mittica P., Bagaglia S.A., Menicacci C., De Cilla’ S., Autelitano A., Fogagnolo P. Blindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye Clinics. PLoS One. 2015;10:8(e0136632). DOI: 10.1371/journal.pone.0136632

5. Bourne R.R., Jonas J.B., Flaxman S.R., Keeffe J., Leasher J., Naidoo K., Parodi M.B., Pesudovs K., Price H., White R.A., Wong T.Y., Resnikoff S., Taylor H.R. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98:629–638. DOI: 10.1136/bjophthalmol-2013-304033. PMID: 24665132.

6. Peters D., Bengtsson B., Heijl A. Lifetime risk of blindness in open-angle glaucoma. Am J Ophthalmol. 2013;156(4):724–730. DOI: 10.1016/j.ajo.2013.05.027

7. Alekseev V.N., Martynova E.B. New approaches to the hypotensive therapy of primary open-angle glaucoma. Cons. Medicum. 2001;3:3–9 (In Russ.).

8. Nesterov A.P. Primary open-angle glaucoma: pathogenesis and treatment principles. Clinical Ophthalmology = Klinicheskaya oftal’mologiya. 2000;1:4–5 (In Russ.).

9. Garudadri C., Senthil S., Khanna R.C., Sannapaneni K., Rao H.B. Prevalence and risk factors for primary glaucomas in adult urban and rural populations in the Andhra Pradesh Eye Disease Study. Ophthalmology. 2010 Jul;117(7):1352–1359. DOI: 10.1016/j.ophtha.2009.11.006

10. Foster P., Johnson G. Glaucoma in China: how big is the problem? Br J Ophthalmol. 2001 Nov;85(11):1277–1282. PMID: 11673287. PMCID: PMC1723754.

11. Kiseleva O.A., Robustova O.V., Bessmertnyy A.M., Zakharova Ye.K., Avdeyev R.V. The prevalence of primary glaucoma among representatives of different races and ethnic groups in the world. review. Ophthalmology in Russia = Oftal’mologiya. 2013;3:5–7 (In Russ.). DOI: 10.18008/1816-5095-2013-3-5-8

12. Neroev V.V., Kiseleva O.A., Bessmertnyy A.M. The main results of a multicenter study of the epidemiological features of primary open-angle glaucoma in the Russian Federation. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2013;6 (3):43–46 (In Russ.).

13. Onishchenko A.L., Kolbasko A.V. Zhilina N.M., Zakharova A.V. Vlasenko A.E. The incidence of primary glaucoma, its gender features among residents of a large industrial city of Siberia. Ophthalmology in Russia = Oftal’mologiya. 2014;11(4):59–66 (In Russ.). DOI: 10.18008/1816-5095-2014-4-59-67

14. Quigley H.A., Broman A. The number of persons with glaucoma worldwide in 2010 and 2020.Br J Ophthalmol. 2006 Mar;90(3):262–267. DOI: 10.1136/bjo.2005.081224

15. Lim M.C., Lim L.S., Gazzard G., Husain R., Chan Y.H., Seah S.K., Aung T. Lens opacity, thickness, and position in subjects with acute primary angle closure. J Glaucoma. 2006 Jun;15(3):260–263. DOI: 10.1097/01.ijg.0000212212.10395.76

16. Ozaki M., Nongpiur M.E., Aung T., He M., Mizoguchi T. Increased lens vault as a risk factor for angle closure: confirmation in a Japanese population. Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1863–1868. DOI: 10.1007/s00417-012-2011-y

17. Song P., Wang J., Bucan K., Theodoratou E., Rudan I., Chan K.Y. National and subnational prevalence and burden of glaucoma in China: A systematic analysis. Journal of global health. 2017;7(2):1–16. DOI: 10.7189/jogh.07.020705

18. Leske M.C., Heijl A., Hyman L., Bengtsson B., Dong L., Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965–1972. DOI: 10.1016/j.ophtha.2007.03.016

19. Baranov V.I., BrezhnevA.Yu. Pseudoexfoliation syndrome in Central Russia: a clinical and epidemiological study. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2012;1:22–24 (In Russ.).

20. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002;120(10):1268–1279.

21. Kuroyedov A.V., Krinitsyna E.A., Sergeeva V.M., Gorodnichi V.V. Changes in the structure of clinical and epidemiological characteristics of primary open-angle glaucoma over 10 years in patients coming to surgical treatment. Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2017; 4:205–212 (In Russ.).

22. Astakhov Yu.S., Nechiporenko P.A. Prostaglandin analogues: past, present, and future. Ophthalmology journal = Oftal’mologicheskie vedomosti. 2017;10(1):40–52 (In Russ.). DOI: 10.17816/ OV10140-52

23. Lewis R.A., Levy B., Ramirez N., Kopczynski C.C., Usner D.W., Novack G.D. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016 Mar;100(3):339–344. DOI: 10.1136/bjophthalmol-2015-306778

24. Kuroyedov A.V., Nagornova Z.M., Tibieva Z.U., Krinitsyna E.A., Sergeeva V.M. Additive and combined glaucoma therapy: principles and practice. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2018;11(2):71–81(In Russ.). DOI: 10.21516/2072-0076-2018-11-2-71-81

25. Martinez A., Sanchez M. Intraocular pressure lowering effect of dorzolamide / timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. Curr. Opin. Ophthalmol. 2007;23(3):595–599. DOI: 10.1185/030079906X167688

26. Hommer A., Hubatsch D.A., Cano-Parra J. Safety and Efficacy of Adding Fixedcombination brinzolamide/timolol maleate to prostaglandin therapy for treatment of ocular hypertension or glaucoma. J Ophthalmol. 2015;2015:131970. DOI: 10.1155/2015/131970

27. Feldman R., Katz G., McMenemy M., Hubatsch D.A., Realini T. A randomized trial of fixed-dose combination brinzolamide 1 %/brimonidine 0.2 % as adjunctive therapy to travoprost 0.004 %. Am. J. Ophthalmol. 2016;165(5):188–197. DOI: 10.1016/j. ajo.2016.02.026

28. Kurysheva N.I., Trubilin V.N., Kapkova S.G., Yuzhakova O.I. Selective laser trabeculoplasty in the treatment of pseudoexfoliative glaucoma. Glaucoma = Glaukoma. 2006;1:20–24 (In Russ.).

29. Shazly T.A., Smith J., Latina M.A. Long-term safety and efficacy of selective laser trabeculoplasty as primary therapy for the treatment of pseudoexfoliation glaucoma compared with primary open-angle glaucoma. Clin Ophthalmol. 2010 Dec 16;5:5–10. DOI: 10.2147/OPTH.S15952

30. Musch D.C., Gillespie B.W., Lichter P.R., Niziol L.M., Janz N.K. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology. 2009 Feb;116(2):200–207. DOI: 10.1016/j.ophtha.2008.08.051

31. Machekhin V.A., Fabrikantov O.L, Lvov V.A. Clinical and demographic characteristics of patients operated on for glaucoma. Ophthalmology in Russia = Oftal’mologiya. 2018;15(2S):220–224 (In Russ.). DOI: 10.18008/1816-5095-2018- 2S-220-224

32. Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. American Journal of Ophthalmology. 1998;126(4):487–497.

33. Herman D.C., Gordon M.O., Beiser J.A., Chylack L.T. Jr, Lamping K.A., Schein O.D., Soltau J.B., Kass M.A. Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol. 2006 Nov;142(5):800–810. DOI: 10.1016/j.ajo.2006.06.052

34. Avdeev R.V., Alexandrov A.S., Bakunina N.A., et al. Comparison of treatment regimens of patients with primary open-angle glaucoma with the characteristics of disease progression. Part 1. National Journal of Glaucoma = Natsional’nyy zhurnal glaukoma. 2018;17(1):14–29 (In Russ.). DOI: 10.25700/NJG.2018.01.02